RxDoctor Payments Data

Keefe Lobb, DO

Family Medicine · Midlothian, VANPI 1972890523

Payments from drug & device makers

$7,147in general payments, 2019–2025

Across 449 payments — averaging $15.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$771
  • Novo Nordisk$705
  • Pfizer$635
  • AstraZeneca$578
  • Lilly USA, LLC$498
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$7,131100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,147 in reported general payments places this provider in the 90th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$136,986
Medicare patients
453
Services billed
2,218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide68$113,966
EliquisApixaban80$79,295
JardianceEmpagliflozin53$59,193
TrulicityDulaglutide30$40,097
MounjaroTirzepatide36$39,976
XareltoRivaroxaban34$30,255
LinzessLinaclotide28$29,360
JanuviaSitagliptin Phosphate18$20,504
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$17,360
Breo ElliptaFluticasone/Vilanterol24$16,931
FarxigaDapagliflozin Propanediol19$11,827
JanumetSitagliptin Phos/Metformin Hcl20$11,732
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$10,252
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$8,746
Ondansetron Hcl13$7,199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$705$113,96668 claims
Lilly USA, LLCTrulicity, Mounjaro$498$80,07366 claims
PfizerEliquis$635$79,29580 claims
Boehringer IngelheimJardiance$205$59,19353 claims
MerckJanuvia, Janumet$211$32,23638 claims
Johnson & JohnsonXarelto$73$30,25534 claims
AbbVieLinzess$1,332$29,36028 claims
GSKBreo Ellipta, Trelegy Ellipta$49$25,67736 claims
AstraZenecaFarxiga, Breztri Aerosphere$578$22,08034 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$2,994327 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Midlothian

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →